Entrada Therapeutics Inc. highlighted plans to expand its neuromuscular pipeline, targeting five clinical-stage programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 by the end of 2026. The company outlined expected 2026 clinical data readouts for ENTR-601-44 and ENTR-601-45, progress toward global regulatory clearances for ENTR-601-50 and filings for ENTR-601-51, and updates on partnered DM1 candidate VX-670, for which the multiple ascending dose portion of a Phase 1/2 study is expected to complete in mid-2026. Entrada also noted an ocular program, including ENTR-801 for Usher syndrome type 2A and a second inherited retinal disease candidate planned for declaration in the second half of 2026, and reported a cash balance of about $296 million as of year-end 2025 with runway into Q3 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.